1st Patient Dosed in Phase 3 Trial of Injectable MarzAA

1st Patient Dosed in Phase 3 Trial of Injectable MarzAA

294080

1st Patient Dosed in Phase 3 Trial of Injectable MarzAA

The first participant has been dosed in a Phase 3 clinical trial testing marzeptacog alfa activated (MarzAA), an experimental under-the-skin therapy for hemophilia A and B patients with inhibitors. The study, called Crimson-1 (NCT04489537) and sponsored by the therapy’s developer, Catalyst Biosciences, is currently recruiting patients at sites in Spain, Ukraine, Poland, Russia, Georgia, India, and Turkey. Additional sites are expected to open in the U.S., U.K., and other countries around the world. “Dosing the first patient…

You must be logged in to read/download the full post.